Antihistamines (cetirizine and loratadine) and antileukotriene (montelukast) in the prevention of allergic rhinitis symptoms Source: Eur Respir J 2003; 22: Suppl. 45, 103s Year: 2003
The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Safety and efficacy of the inhaled pan-selectin antagonist bimosiamose in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 613s Year: 2007
Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006
Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007
Safety and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children Source: Eur Respir J 2002; 20: 104-107 Year: 2002
Lung function, pharmacokinetics, and tolerability of indacaterol maleate and acetate in asthma patients Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Source: Eur Respir J 2012; 40: 1106-1114 Year: 2012
Pharmacokinetics (PK), safety and tolerability of abediterol and mometasone furoate fixed- and free-dose combinations in healthy subjects Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
No relevant drug-drug interaction between inhaled NVA237 and oral cimetidine Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Cardiac safety of indacaterol, a novel once-daily bronchodilator, in asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Dose-ranging study to assess the efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019
Comparison between zafirlukast and two fluticasone doses in asthma treatment Source: Eur Respir J 2005; 26: Suppl. 49, 368s Year: 2005
Anti-inflammatory effect and clinical efficacy of concomitant treatments to steroid inhaler in bronchial asthma: montelukast versus salmeterol Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006
Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Efficacy and safety of Long-acting Beta-agonists+Long-acting muscarinic antagonists vs Long-acting Beta-agonists+Inhaled corticosteroids in COPD: a meta-analysis Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017
Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011